A Single-Centre, Placebo-Controlled, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AZD3241 Following Administration of Single Ascending (Part A) and Fractionated Ascending (Part B) Oral Doses to Young Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 26 Aug 2008
At a glance
- Drugs AZD 3241 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- 26 Aug 2008 New trial record.